Global, regional, and national burden of kidney, bladder, and prostate cancers and their attributable risk factors, 1990–2019

Abstract

Background The burden of kidney, bladder, and prostate cancers has changed in recent decades. This study aims to investigate the global and regional burden of, and attributable risk factors for genitourinary cancers during the past 30 years. Methods We extracted data of kidney, bladder, and prostate cancers from the Global Burden of Disease 2019 database, including incidence, mortality, disability-adjusted life-years (DALYs), and attributable risk factors from 1990 to 2019. Estimated annual percentage changes (EAPC) were calculated to assess the changes in age-standardized incidence rate, age-standardized mortality rate (ASMR), and age-standardized DALYs rate (ASDR). The associations between cancers burden and socio-demographic index (SDI) were also analyzed. Results Compared with 1990, the global incident cases in 2019 were higher by 154.78%, 123.34%, and 169.11% for kidney, bladder, and prostate cancers, respectively. During the 30-year study period, there was a downward trend in ASMR and ASDR for bladder cancer (EAPC = − 0.68 and − 0.83, respectively) and prostate cancer (EAPC = − 0.75 and − 0.71, respectively), but an upward trend for kidney cancer (EAPC = 0.35 and 0.12, respectively). Regions and countries with higher SDI had higher incidence, mortality, and DALYs for all three types of cancers. The burden of bladder and prostate cancers was mainly distributed among older men, whereas the burden of kidney cancer increased among middle-aged men. Smoking related mortality and DALYs decreased, but high body mass index (BMI) and high fasting plasma glucose (FPG) related mortality and DALYs increased among kidney, bladder, and prostate cancers during the study period. Conclusions Kidney, bladder, and prostate cancers remain major global public health challenges, but with distinct trend for different disease entity across different regions and socioeconomic status. More proactive intervention strategies, at both the administrative and academic levels, based on the dynamic changes, are needed.

Overall and Cancer-Specific Survival in Patients With Renal Pelvic Transitional Cell Carcinoma: A Population-Based Study

“…Genitourinary cancer remains a major public health problem, and their incidence and mortality rates have changed significantly in recent decades ( 27 ). Therefore, there is an urgent need to develop effective predictive tools to guide cancer prevention and treatment.…”

Nanomaterials-Based Urinary Extracellular Vesicles Isolation and Detection for Non-invasive Auxiliary Diagnosis of Prostate Cancer

“…In 2020, PCa has the highest cancer-related incidence in countries with a low human development index and is the fifth leading cause of cancer death in men, which has brought great problems to men's life and health (87). The etiologies of PCa are numerous and complex, which make early accurate diagnosis difficult (88,89). As we all know, PSA is a common indicator used in PCa detection, and population-based PSA screening for patients with PCa can reduce the mortality to a certain extent.…”

Identification of a Three-Glycolysis-Related lncRNA Signature Correlated With Prognosis and Metastasis in Clear Cell Renal Cell Carcinoma

“…Renal cell carcinoma (RCC) ranks seventh of the most serious types of malignancies worldwide ( 1 ), maintaining the highest morbidity among kidney cancer and demonstrating an upward trend over the past 30 years ( 2 ). Clear cell renal cell carcinoma (ccRCC) is the most common pathologically RCC subtype that accounts for 85–90% of cases ( 3 ).…”